Ryan Weispfenning | VP and Head, IR |
Geoff Martha | Chairman and CEO |
Karen Parkhill | CFO |
Sean Salmon | EVP and President, Cardiovascular Portfolio |
Bob White | EVP and President, Medical Surgical Portfolio |
Brett Wall | EVP and President, Neuroscience Portfolio |
Que Dallara | EVP and President, Diabetes Operating Unit |
Robbie Marcus | JPMorgan |
Vijay Kumar | Evercore ISI |
Travis Steed | Bank of America Global Research |
Cecilia Furlong | Morgan Stanley |
Larry Biegelsen | Wells Fargo Securities |
Joanne Wuensch | Citi |
Jayson Bedford | Raymond James |
Steve Lichtman | Oppenheimer & Co. |
Rich Newitter | Truist Securities |
Rick Wise | Stifel, Nicolaus & Company |
Good morning, and welcome to Medtronic’s Fiscal Year 2023 First Quarter Earnings Broadcast. I’m Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations. I’m inside one of our Medtronic mobile labs, which is making a stop here at our operational headquarters in Minneapolis. These high-tech mobile classrooms will give about 5,000 U.S. clinicians every year the opportunity to train on some of our most advanced state-of-the-art technology, including our O-arm and StealthStation.